Pharmaceutical Executive-07-01-2008

Rejection is tough to take, but leaders have the drive and ability to bounce back from a setback with boundless energy

It's not that I disagree with the Obama and McCain healthcare proposals. It's that there's nothing actually there to disagree with

Rare disease treatments are riding high as patient adcovates, pharma companies, and government officials celebrate the ODA's 25th anniversary

Genentech had previously been number one by a very wide margin. This year, that margin started to narrow. Novartis is now a much closer second

An innovative approach bridges the pediatric communication gap

A look at some of the court cases that could actually change the pharma playing field

A strict marketing regimen will help keep your brand healthy in the digital

Could gene silencing be the next great innovation in drug development? Some biotechs are betting on it.

No, it's not as glamorous as its double-helixed offspring. But recent revelations about RNA turn even cold-eyed scientists into lyrical romantics